GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » Forward PE Ratio

Aytu BioPharma (STU:AY20) Forward PE Ratio : 8.34 (As of May. 04, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma Forward PE Ratio?

Aytu BioPharma's Forward PE Ratio for today is 8.34.

Aytu BioPharma's PE Ratio without NRI for today is 0.00.

Aytu BioPharma's PE Ratio (TTM) for today is 0.00.


Aytu BioPharma Forward PE Ratio Historical Data

The historical data trend for Aytu BioPharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Forward PE Ratio Chart

Aytu BioPharma Annual Data
Trend 2020-06 2024-06
Forward PE Ratio
11.90 4.32

Aytu BioPharma Quarterly Data
2020-06 2023-03 2024-03 2024-06 2024-09
Forward PE Ratio 11.90 11.33 5.87 4.32 4.13

Competitive Comparison of Aytu BioPharma's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Forward PE Ratio falls into.


;
;

Aytu BioPharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Aytu BioPharma  (STU:AY20) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Aytu BioPharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines